FDA grants regular approval for Tabrecta use in NSCLC after follow-up data
GlobalData expects Novartis’ Tabrecta to maintain its US market-leading position in non-small cell lung cancer (NSCLC).
By
GlobalData expects Novartis’ Tabrecta to maintain its US market-leading position in non-small cell lung cancer (NSCLC).
ByProgression-free survival is the primary endpoint of the Phase II portion of the trial.
The chimeric endocrine receptor T-cell therapy of the company acts on the follicle stimulating hormone receptor.
The Clinical Trials Arena team also investigate treatment candidates in colorectal cancer, retinal vein occlusion, and Raynaud’s disease.
ByThe investigator-sponsored, open-label, single-arm, multicentre trial is being managed by contract research organisation Criterium.
The trial will assess the safety and efficacy of GLSI-100 in patients with HER2/neu positive breast cancer.
The Phase II expansion portion of the trial will assess GDA-201’s safety and efficacy in two cohorts of 63 subjects.
The trial will assess the safety, tolerability, pharmacokinetics and initial antitumor activity of PEEL-224.
Thank you for subscribing to Clinical Trials Arena